EA202092251A1 - Комбинированные продукты для лечения rsv - Google Patents
Комбинированные продукты для лечения rsvInfo
- Publication number
- EA202092251A1 EA202092251A1 EA202092251A EA202092251A EA202092251A1 EA 202092251 A1 EA202092251 A1 EA 202092251A1 EA 202092251 A EA202092251 A EA 202092251A EA 202092251 A EA202092251 A EA 202092251A EA 202092251 A1 EA202092251 A1 EA 202092251A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methyl
- compound
- imidazo
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16154035 | 2016-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092251A1 true EA202092251A1 (ru) | 2020-12-11 |
Family
ID=55304886
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092251A EA202092251A1 (ru) | 2016-02-03 | 2017-02-02 | Комбинированные продукты для лечения rsv |
| EA202092250A EA202092250A1 (ru) | 2016-02-03 | 2017-02-02 | Комбинированные продукты для лечения rsv |
| EA201891655A EA037206B1 (ru) | 2016-02-03 | 2017-02-02 | Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092250A EA202092250A1 (ru) | 2016-02-03 | 2017-02-02 | Комбинированные продукты для лечения rsv |
| EA201891655A EA037206B1 (ru) | 2016-02-03 | 2017-02-02 | Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10363253B2 (enExample) |
| EP (2) | EP3411028B1 (enExample) |
| JP (1) | JP7065030B2 (enExample) |
| KR (1) | KR20180108598A (enExample) |
| CN (2) | CN108601774B (enExample) |
| AU (2) | AU2017214246B2 (enExample) |
| BR (1) | BR112018014958A2 (enExample) |
| CA (1) | CA3006488A1 (enExample) |
| CL (3) | CL2018001808A1 (enExample) |
| EA (3) | EA202092251A1 (enExample) |
| ES (1) | ES2877808T3 (enExample) |
| IL (2) | IL259669B (enExample) |
| MX (2) | MX2020012592A (enExample) |
| MY (1) | MY197217A (enExample) |
| PH (2) | PH12020551598B1 (enExample) |
| SG (1) | SG11201806581TA (enExample) |
| UA (1) | UA124099C2 (enExample) |
| WO (1) | WO2017134133A1 (enExample) |
| ZA (1) | ZA201805205B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6675407B2 (ja) | 2014-10-10 | 2020-04-01 | プルモシデ リミテド | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
| WO2016097761A1 (en) | 2014-12-18 | 2016-06-23 | Pulmocide Limited | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections |
| WO2017175000A1 (en) | 2016-04-08 | 2017-10-12 | Pulmocide Limited | Compounds |
| TW201936193A (zh) | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療ｒｓｖ |
| MX2022005257A (es) * | 2019-10-30 | 2022-06-09 | Janssen Sciences Ireland Unlimited Co | Sintesis de 3-({5-cloro-1-[3-(metilsulfonil)propil]-1h-indol-2-il} metil)-1-(2,2,2-trifluoroetil)-1,3-dihidro-2h-imidazo[4,5-c]pirid in-2-ona. |
| CN114014856B (zh) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物 |
| CN116077494A (zh) * | 2023-01-11 | 2023-05-09 | 黑龙江中医药大学 | 一种治疗呼吸道合胞病毒的药物组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI515187B (zh) * | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| AU2014259474B2 (en) * | 2013-04-25 | 2018-09-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble prefusion RSV F polypeptides |
| PH12021550330A1 (en) * | 2013-08-21 | 2022-09-28 | Janssen Biopharma Inc | Antiviral compounds |
| JP6675407B2 (ja) | 2014-10-10 | 2020-04-01 | プルモシデ リミテド | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
-
2017
- 2017-02-02 MY MYPI2018001388A patent/MY197217A/en unknown
- 2017-02-02 EA EA202092251A patent/EA202092251A1/ru unknown
- 2017-02-02 CN CN201780009640.0A patent/CN108601774B/zh not_active Expired - Fee Related
- 2017-02-02 JP JP2018540796A patent/JP7065030B2/ja not_active Expired - Fee Related
- 2017-02-02 ES ES17702125T patent/ES2877808T3/es active Active
- 2017-02-02 EP EP17702125.0A patent/EP3411028B1/en active Active
- 2017-02-02 AU AU2017214246A patent/AU2017214246B2/en not_active Ceased
- 2017-02-02 EA EA202092250A patent/EA202092250A1/ru unknown
- 2017-02-02 MX MX2020012592A patent/MX2020012592A/es unknown
- 2017-02-02 EA EA201891655A patent/EA037206B1/ru unknown
- 2017-02-02 PH PH1/2020/551598A patent/PH12020551598B1/en unknown
- 2017-02-02 CA CA3006488A patent/CA3006488A1/en active Pending
- 2017-02-02 BR BR112018014958-6A patent/BR112018014958A2/pt not_active Application Discontinuation
- 2017-02-02 WO PCT/EP2017/052201 patent/WO2017134133A1/en not_active Ceased
- 2017-02-02 CN CN202010988991.4A patent/CN112245429A/zh active Pending
- 2017-02-02 UA UAA201809060A patent/UA124099C2/uk unknown
- 2017-02-02 KR KR1020187020776A patent/KR20180108598A/ko not_active Withdrawn
- 2017-02-02 EP EP21170919.1A patent/EP3892273A3/en not_active Withdrawn
- 2017-02-02 US US16/075,103 patent/US10363253B2/en active Active
- 2017-02-02 SG SG11201806581TA patent/SG11201806581TA/en unknown
- 2017-02-02 MX MX2018009422A patent/MX381654B/es unknown
-
2018
- 2018-05-29 IL IL259669A patent/IL259669B/en active IP Right Grant
- 2018-06-29 CL CL2018001808A patent/CL2018001808A1/es unknown
- 2018-08-02 ZA ZA2018/05205A patent/ZA201805205B/en unknown
- 2018-08-02 PH PH12018501649A patent/PH12018501649B1/en unknown
-
2019
- 2019-05-29 CL CL2019001454A patent/CL2019001454A1/es unknown
- 2019-05-29 CL CL2019001455A patent/CL2019001455A1/es unknown
-
2020
- 2020-09-10 IL IL277281A patent/IL277281B/en active IP Right Grant
-
2022
- 2022-03-25 AU AU2022202070A patent/AU2022202070A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092250A1 (ru) | Комбинированные продукты для лечения rsv | |
| CY1125460T1 (el) | Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus | |
| JP2019504102A5 (enExample) | ||
| RU2007146390A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| MA39162A1 (fr) | Composés nicotinamide substitués par un hétéroaryle | |
| FI3805222T3 (fi) | 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa | |
| EA200600064A1 (ru) | Производные тиенопиридона как ингибиторы киназ | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| PE20150723A1 (es) | Compuestos antiviricos para el vsr | |
| JP2016538316A5 (enExample) | ||
| MX392531B (es) | Formas morficas de g1t38 y metodos de preparacion de las mismas. | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| MXPA01003855A (es) | Combinaciones de antagonistas del factor de liberacion de corticotropina y secretagogos de hormona del crecimiento. | |
| ATE486602T1 (de) | Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose | |
| IL282786B2 (en) | (N-(3-(imidazo[5,4-d]pyrrolo[3,2-b]pyridin-1(6H)-yl(bicyclo[1.1.1]pentan-1-yl)-1-sulfonamide derivatives as Janus kinase 1 inhibitors, compositions and methods thereof | |
| EA201891897A1 (ru) | 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1 | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| RU2017139254A (ru) | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата | |
| AR106647A1 (es) | Compuesto piranodipiridínico | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA202091363A1 (ru) | Лечение rsv комбинированным продуктом | |
| MX383514B (es) | Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa. | |
| RU2022104462A (ru) | Фармацевтические соединения |